(Boursier.com) – Advicenna has entered into an exclusive distribution partnership with FrostPharma AB, a Swedish pharmaceutical company, for the marketing of Sibnayal in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden).
The partnership with FrostPharma is the third signed by Advicenne for the commercialization of Sibnayal in Europe, after recent collaboration agreements with TwinPharma in the Benelux and ExCEEd Orphan in Central and Eastern Europe. These three partners participate in an exclusive European network, “Your Pharma Partner”, whose role is to provide patients with innovative therapies in 25 European countries. With these three agreements, Sibnayal will be made available to nearly a third of European patients.
Sibnayal is the first and only drug indicated for the treatment of Distal Renal Tubular Acidosis (dDAT) in adults, adolescents and children over 1 year of age. The indication for Sibnayal in the treatment of dATR was issued by the European Medicines Agency (EMA) in May 2021.
Under the terms of the agreement, FrostPharma has exclusive rights to market Sibnayal in its indication in the territories defined in the contract. In return, Advicenne will receive the proceeds from the sale of Sibnayal in the form of a transfer price and royalties for a combined amount significantly greater than 50% of future sales. FrostPharma already manages the Early Access Program (EAP) of Sibnayal in Sweden.
© 2022 Boursier.com